3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Advanced Solid Tumors
1
Interventions
pembrolizumab
20
Cisplatin
14
Carboplatin
13
Paclitaxel
12
Radiation
11
Doxorubicin
10
Radiotherapy
9
Nivolumab
9
Cyclophosphamide
9
Cytarabine
8
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Metformin
7
Magnetic Resonance Spectroscopy
7
Etoposide
7
Leucovorin
6
Ipilimumab
6
Injections
6
Fluorouracil
6
Docetaxel
6
tislelizumab
5
Specimen Handling
5
Radiotherapy, Conformal
5
Prednisone
5
Pemetrexed
5
Methotrexate
5
Cetuximab
5
Bevacizumab
5
fludarabine
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Antiemetics
×
30 days
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts